Wolfe Eye Clinic Vitreoretinal Diseases and Surgery Fellowship
The Wolfe Eye Clinic will offer fellowship training in Vitreoretinal Diseases and Surgery beginning in July 2019. The 24 month surgical and medical retina fellowship, based in West Des Moines, Iowa, will offer exceptional clinical and surgical volume in a state of the art facility dedicated to the expert care of retina patients. Fellows will enjoy a collegial atmosphere in a busy retina clinic with a high level of ancillary support. The fellowship is currently unopposed with one fellow taken every 2 years, giving the fellow the opportunity to submerse in retina clinical care and participate in over 1000 OR cases. In addition to the medical and surgical care of retina patients, the fellow will directly participate in various industry-sponsored clinical trials ongoing in our active clinical research department. Fellows will participate in regular educational sessions and have the time and support to participate and present at national meetings. The fellow will be provided with the mentorship, didactics, and direct exposure to the business and mechanics of retina practice enabling them to pursue a retina career at the highest level.
$85,000/year + benefits
3 weeks + educational time
Annual Retina Clinical/Surgical Volume:
Retina Patient Visits: 35,000+
Office Procedures (injections/lasers): 25,000 +
Operating Room Surgical Procedures: 500 +
– Topics in Vitreoretinal Diseases and Surgery, Weekly
– Imaging and Case Conference, Monthly
– Journal Club, Monthly
– Regional Retina Meetings, varies
– Annual Retina Meeting (ASRS, AAO Subspecialty, Retina Society)
– National Fellow meetings
Current Clinical Trials:
Diabetic Retinopathy Clinical Research Network (DRCR.net); Sponsor: National Eye Institute and the National Institute of Health:
– Protocol AA: Peripheral DR Lesions on Ultrawide-Field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time,
– Protocol W: Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk,
– Genes in Diabetic Retinopathy Project
– Protocol Tx: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
– Protocol AD: PROMINENT-Eye Ancillary Study
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER) Sponsor: Roche/Genentech
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) (TIME-2b) Sponsor: Aerpio
Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration, Sponsor: Ophthotech
Phase 4 IOP Signals Associated With ILUVIEN® (PALADIN) Sponsor: Alimera Sciences
Other trials beginning this fall to be announced.
September 15, 2018
Apply through SFMatch.org.
Fellows must have completed an Accredited US Ophthalmology Residency and be ABO board eligible, a US Citizen or holder of appropriate VISA and eligible for unrestricted Iowa Medical licensure. Please note that fellowship appointment will require signing a covenant limiting the ability to practice in geographic locations surrounding all Wolfe Clinic locations.
For Additional Information Contact:
Carter Roberts, MHA